MeSH term
Frequency | Condition_Probility | Chromosome Mapping | 5 | 0.0 |
Genetic Predisposition to Disease/*genetics | 6 | 1.0 |
Humans | 54 | 0.0 |
*Loss of Heterozygosity | 3 | 0.0 |
Male | 40 | 0.0 |
Prostatic Neoplasms/*genetics | 20 | 11.0 |
Research Support, Non-U.S. Gov't | 39 | 0.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Aged | 20 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Female | 11 | 0.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
Middle Aged | 21 | 0.0 |
Neoplasm Staging | 5 | 0.0 |
Alleles | 3 | 0.0 |
Prostatic Neoplasms/epidemiology/*genetics | 2 | 15.0 |
Age of Onset | 6 | 0.0 |
Chromosomes, Human, Pair 1/*genetics | 12 | 5.0 |
DNA Mutational Analysis | 4 | 0.0 |
Finland | 2 | 0.0 |
Gene Frequency | 3 | 0.0 |
Pedigree | 12 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 26 | 0.0 |
Base Sequence | 9 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Endoribonucleases/*genetics | 3 | 30.0 |
Heterozygote | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
*Oncogenes | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Genetic Predisposition to Disease/genetics | 5 | 1.0 |
Risk Factors | 5 | 0.0 |
Adult | 7 | 0.0 |
Prostatic Neoplasms/*genetics/pathology | 2 | 2.0 |
Gene Expression | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Family Health | 3 | 0.0 |
Genetic Markers/genetics | 4 | 0.0 |
Genotype | 11 | 0.0 |
Lod Score | 9 | 0.0 |
Microsatellite Repeats | 7 | 0.0 |
*Chromosomes, Human, Pair 1 | 7 | 1.0 |
*Linkage (Genetics) | 6 | 0.0 |
Amino Acid Sequence | 11 | 0.0 |
Animals | 12 | 0.0 |
Contig Mapping | 2 | 1.0 |
DNA, Complementary | 3 | 0.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Neoplastic Syndromes, Hereditary/*genetics | 2 | 4.0 |
Rats | 9 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Genetic Heterogeneity | 3 | 1.0 |
Models, Genetic | 3 | 0.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
X Chromosome/genetics | 2 | 1.0 |
Family | 2 | 0.0 |
Prostatic Neoplasms/*ethnology/*genetics | 2 | 50.0 |
United States | 2 | 0.0 |
Cell Line | 4 | 0.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Prostatic Neoplasms/*epidemiology/*genetics | 2 | 28.0 |
Genetic Markers | 4 | 0.0 |
Gene Deletion | 2 | 0.0 |
Proprotein Convertases | 8 | 17.0 |
Age Factors | 4 | 0.0 |
Linkage (Genetics)/*genetics | 3 | 1.0 |
*Lod Score | 2 | 5.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
*Genome, Human | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Disease Susceptibility | 4 | 0.0 |
Sweden | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
*Alleles | 2 | 0.0 |
*X Chromosome | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Mice | 6 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Furin | 3 | 6.0 |
Kinetics | 4 | 0.0 |
Substrate Specificity | 4 | 0.0 |
Subtilisins/*antagonists & inhibitors | 2 | 50.0 |
Transfection | 3 | 0.0 |
Comparative Study | 7 | 0.0 |
*Proprotein Convertase 1 | 5 | 33.0 |
Structure-Activity Relationship | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
DNA Probes/genetics | 2 | 1.0 |
Phosphorylation | 2 | 0.0 |
Pituitary Hormones/chemistry/*genetics/metabolism | 2 | 100.0 |
Serine Endopeptidases/chemistry/*genetics/metabolism | 2 | 33.0 |
Swine | 2 | 0.0 |
Tissue Distribution | 3 | 0.0 |
